Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BMSN Aim High Profits Article...
http://www.aimhighprofits.com/bmsn-bio-matrix-scientific-has-a-billion-chances-for-gains-22797
BMSN | Bio-Matrix Scientific Has A Billion Chances For Gains
January is, and has been, Biotech month. With conferences in San Francisco wrapping up just in time for the AFC divisional playoff game this weekend, news flow will begin to hit the street of deals and JVA in the coming days and weeks. One penny stock many traders are speculating will have some positive momentum is that of Bio-Matrix Scientific Group Inc. (OTC: BMSN). Used by many seasoned traders as an ATM card of sorts, BMSN stock is a target of many to follow the path another break out biotech had from September whereby $500 would have yielded over $20,000 in the course of just 3 months.
BMSN Stock Chart
Market Cap: 282.03K
Last: 0.0013 ? 0.0002 (18.18%)
Volume: 50,060,297
Dollar Volume: $52,934
Open: 0.0011
High: 0.0013
Low: 0.0009
Trades: 105
Authorized: 2,000,000,000
Issued and Outstanding: 1,035,911,549
14-Day Rel Strength: 58.56%
14-Day Stochastic: 50.00%
As of 8AM Friday, Bio-Matrix Scientific Group is late in filing their 10-K which is surely why CEO, David Koos, felt it appropriate to issue the 8-K indicating the number of issued and outstanding shares as of December 31, 2012. Revenues will not be listed unless an agreement, which no one knows of, was made prior to the end of the year involving their wholly-owned subsidiary, Regen BioPharma, Inc.
In mid November, a safety and efficacy test of Regen’s HemaXellerate™ product using mice models for testing was said to begin by Cascade Life Sciences, Inc. Positive results from the test would have led to a safety profile data required for filing of an Investigational New Drug application for the product with the US Food and Drug Administration. The plan was for Regen BioPharma to file the application during Q4, 2012 with Phase I/II clinical trials expected to begin during 2013 and 2014 upon approval.
News or not, BMSN stock is a pure speculation play at present. For months, veteran penny stock traders have utilized the trading pattern as a sort of ATM card by swing trading it effectively. With new coverage beginning by the same groups who brought Amarantus BioScience, Inc. (AMBS) to the surface, the chances of a PR issuance about Regen BioPharma could crush the bid, sending BMSN past its 200 day moving average, 0.0038, or even to its 2012 summer levels of 0.062 even though less than half the number of shares were outstanding at that time.
About BMSN Stock
Bio-Matrix Scientific Group, Inc. is a development stage engaged primarily in the business of providing biospecimen depository services , namely offering cryopreservation of cellular specimens as well as laboratory processing of cellular specimens including stem cell banking. Click here to view the SEC filings for BMSN.
Last 5 Trading Sessions:
Date Last Change % Change Volume
01/10/13 0.0013 +0.0002 +18.18% 50,060,297
01/09/13 0.0011 -0.0001 -8.33% 30,973,600
01/08/13 0.0012 unch unch 21,432,500
01/07/13 0.0012 unch unch 109,784,695
01/04/13 0.0012 -0.0002 -14.29% 108,174,602
Bottom Line: BMSN stock is worth a glance, or even a check-in, to see if the penny stock world is showing any love for it. With the huge number of shares which have been issued during the last 3 months, it’s going to take an enormous amount of bullishness to push BMSN stock above 0.005.
The 10Q is due 15 Jan.
Too funny!!
Red Lobster? You stingy bastard
Show me the link with the money to support your claim!!
Fara...I agree! I would rather have a steady climb over a gap up any day!! I just don't want to risk being caught in a gap up and be sold out before I would rather sell. I originally set my sell order at .01 thinking I can always move it up, if desired, based on price movement. However, if it moves too fast tomorrow, I may not have time to react.
I had my sell order set at .01. But will move my price higher just so it doesn't trigger before I think I'm ready for it with the start of the promo now. I'm in for under .001 I'm already very green! Just wish I had the available funds to buy a few more million before we go up!
$BMSN I received an email from AwesomePennyPocks this evening about 2 hrs ago. Just noticed it a few mins ago.
Need to go cancel my sell order and just sit at the L2 screen tomorrow and see where we go!!
Lets roll!!
$BMSN Promo In Play:
Received email 10 Jan 2013 @ 10:46pm CST
from Exclusivestocks and Awesome Penny Picks:
BMSN ~ Our New Vip Pick and the Top Stem Cell Biotech Stock trading at only .0013 cents with huge upside.. BMSN is our next AMBS type play.. Members if you recall AMBS was our last Biotech Vip Pick at .005 cents and it ran to a high of .19 cents recently.. BMSN is our New Biotech Vip Pick and its chart is screaming breakout right now.. BMSN is Pending to Announce FDA IND Application News for its Drug, Safety & Research News on its Drug and Merger News so act fast on this one Members..
BMSN is a biotechnology company developing regenerative medicine therapies. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications. Regen BioPharma, Inc., a subsidiary of BMSN, is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.
BMSN has Assessed over 20,000 Stem Cell related issued Patents, narrowed down to 2000 Patents with commercial applicability, and further identified 30 Patents available for Licensing.
BMSN seeks to inlicense, take the product to, and through clinical safety and efficacy "signal" and spin out technologies. HemaXellerate™ offers the possibility of delivering a population of endothelial cells to restore blood production in patients with hematological conditions. "Unlike current approaches of administering pharmaceuticals," said J. Christopher Mizer, President of Regen BioPharma, "our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally." Regen has submitted two provisional patent applications covering the use of different sources of endothelial cells to heal damaged bone marrow. These applications cover: (1) placental cells (61/648898 - Acceleration 0f Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells); and (2) fat cells (61/670791 - Treatment of Hematopoietic Disorders).
BMSN recently announced Thomas E. Ichim, PhD (view here) has joined the management team of its Regen BioPharma, Inc. subsidiary as Chief Scientific Officer and Director of Research.
Regen BioPharma is the company's translational medicine platform for the rapid commercialization of stem cell therapies. Dr. Ichim is one of the leading authorities in the world on stem cell biology. To date, he has published 82 peer-reviewed articles and is co-editor of the textbook RNA Interference: From Bench to Clinical Translation. He is also inventor on over 30 patents and patent applications. He currently serves as the CEO of Medistem, Inc., was formerly chief of scientific development, and is the scientific founder / co-founder of Medvax Pharma, ToleroTech, bioRASI, and OncoMune. David Koos, Chief Executive Officer of BMSN, stated: "Dr. Ichim is a seasoned biotechnology executive with a track record of scientific excellence. We now have a world-class team to lead our efforts to commercialize stem cell therapies."
BMSN ~ Is Pending to Announce FDA IND Application Breaking News, Safety News and Research News any day now so act fast Members.. BMSN Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate(TM) Cell Therapy
BMSN Also Developing Two Solutions for Restoring Blood Production That Lack the Adverse Effects of Current Bone Marrow Stimulating Growth Factors
SAN DIEGO, CA--(Marketwire - Nov 19, 2012) - Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN) announced today that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate™ product using mice models for testing. Cascade Life Sciences is a privately-owned San Diego-based company with a platform of stem cell related technologies that are being advanced to serve the research community and the commercial development of stem cell-based therapeutics. Sophia Khaldoyanidi, M.D., Ph.D. is the principal investigator of the study.
The results of Regen's study will provide the safety profile data required for filing of an Investigational New Drug (IND) application for the product with the US Food and Drug Administration . Regen intends to file an IND Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014.
HemaXellerate™ offers the possibility of delivering a population of endothelial cells to restore blood production in patients with hematological conditions. "Unlike current approaches of administering pharmaceuticals," said J. Christopher Mizer, President of Regen BioPharma, "our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally."
Regen has submitted two provisional patent applications covering the use of different sources of endothelial cells to heal damaged bone marrow. These applications cover: (1) placental cells (61/648898 - Acceleration 0f Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells); and (2) fat cells (61/670791 - Treatment of Hematopoietic Disorders).
BMSN ~ Announced that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate™ product using mice models for testing.
Cascade Life Sciences is a privately-owned San Diego-based company with a platform of stem cell related technologies that are being advanced to serve the research community and the commercial development of stem cell-based therapeutics. Sophia Khaldoyanidi, M.D., Ph.D. is the principal investigator of the study."
BMSN ~ Breaking Merger News is Pending.. The CEO of BMSN has mentioned its Pending to Announce Merger News with its Majority Owned Subsidiary Entest BioMedical, Inc (OTCBB: ENTB)..
Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of BMSN. The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). Currently, Entest is focused on research and development in areas of COPD and Immuno-Therapeutic Cancer Vaccines. The Company sees applications for its patent pending technologies in both human and animal venues. Immuno-therapeutic treatment of cancer - The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer.
The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment. Chronic Obstructive Pulmonary Disease -There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 BB will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms. Entest BioMedical was founded for the purpose of providing excellence in biotechnology research (including adult stem cell regenerative treatment). Our objectives go beyond developing single products and procedures. Our mission is to discover and develop new procedures, treatments and medical devices that improve the quality of life. Our efforts revolve around a business focus of developing leading research and technology. Ongoing R&D is paramount to us in developing products and procedures with purpose, products and services that serve the present and help shape the future.
BMSN Shows a Monster Breakout coming now as well as the Company's 10K due out on January 15th so act fast on this one Members..
Make sure to Get ready tomorrow morning and pull up BMSN on your quotes and charts cause this one looks to run high short term..
SEC...Please explain??
Nice history of such postings...
http://investorshub.advfn.com/boards/profile.aspx?user=332324
What are you talking about? Please explain!!
Grants...financing...JV agreements with BIG Pharm or other established biotech Co. Buyout offers, even if not accepted would show what other Pharms/biotechs think this is worth!!
SEEKING ALPHA ARTICLE...
http://seekingalpha.com/article/1101761-first-half-of-2013-to-be-a-critical-time-for-exact-sciences?source=yahoo
...In other M&A news in the space, Amarantus BioScience (AMBS.OB), a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, announced the company purchased all of the intellectual property assets from Power3 Medical Products.
As part of the transaction, Amarantus took ownership of 20 pending patent applications covering a variety of biomarkers and assays related to the treatment of various diseases including Parkinson's, Alzheimer's, and ALS, as well as patent applications related to Breast Cancer, neuromuscular disease and Chronic Myelogenous Leukemia. The company also acquired all of the data generated by Power3 while creating its IP portfolio. All of the disease states covered by the intellectual property acquired from Power3 are related to Programmed Cell Death (Apoptosis).
A brief side note, investing in micro-cap stocks is risky as they tend to be new and unproven. Low trading volumes increase liquidity risk.
Pk...I see you got it figured out...I haven't found an easier way to post it yet! lol
Audiboy...Read this article and tell me if it's possible!
http://www.biomedreports.com/2009111818487/ready-to-run-power3-medical-products-otcpwrm.html
The JV with RB hasn't been finalized yet...I'm sure for good reason at this point. I think AMBS is keeping options open until after they have opportunity for presentation and any BIG JV offers and/or advice from other Biotech/Big Pharm companies! JMO
Webcast link from today's PR:
The presentation will be webcast live at the link: http://onemedplace.com/forum/webcast/
Aim High Profits News 5 Jan 2012...
http://www.aimhighprofits.com/ambs-how-to-turn-500-into-20000-amarantus-bioscience-22543
AMBS | How To Turn $500 into $20,000? Amarantus BioscienceEver been told there is a “science” to making money? Three months, 59 trading sessions, less than $50 in commissions. That’s all it took for long investors to realize a 4,139% profit, 1,047% since December 1st alone. It’s crazy, but those with the foresight to put $500 into the penny stock of Amarantus BioScience Inc. (OTC:AMBS) in October, this week it was worth $20,695. The gains have been huge and since entering into the LOI at the end of 2012 with Brewer Sports International, LLC and Toi Cook Management Group, LLC, AMBS stock could be in for a huge run throughout biotech friendly January.
AMBS Stock Chart
Market Cap: 33.77M
Last: 0.1506 ? 0.0009 (0.60%)
Volume: 20,113,241
Dollar Volume: $2,850,432
Open: 0.1519
High: 0.1535
Low: 0.131
Trades: 1,379
14-Day Rel Strength: 69.87%
14-Day Stochastic: 71.35%
On September 21, 2012, after the market had closed, alerts were first issued to kick off the run AMBS stock has been on starting at $0.0051. The predictions made were more accurate and had a bigger impression than many expected. “We’re expecting this one to be a monster. Our last two Biotech’s were Huge Winners and we feel this New Sub-Penny Biotech play could be the top pick in the micro-cap market for 2012.” Check out the amazing stock chart since September 21:
AMBS has had an amazing run so far, and it is looking much like the same pattern Cannabis Science (CBIS) created at the start of 2012. The recent agreement with Brewer Sports International to collaborate in the coordination and co-hosting of an international symposium, #C4CT Concussion Awareness Conference, is set to kick off next week in San Francisco, CA at the OneMedForum and Biotech Showcase.
Amarantus’ efforts to bring attention to their proprietary therapeutic protein Mesencephalic Astrocyte-derived Neurotrophic Factor, MANF, is in the hot seat this week, as is AMBS stock. Bringing thought leaders in the field of Traumatic Brain Injury drug and diagnostic research & development is focused on more than just professional athletes, former professional athletes and celebrity sports figureheads that share the Company’s desire to support research into new TBI treatments.
Brain degenerative diseases that were once designated for people in their 70's and 80's are now showing up in 50-to-60 year-olds, sometimes even as early as the 30’s and 40’s. Compounding the problem is the medical industry’s often mistakenly missed diagnosis of the early stages of Alzheimer’s, dementia, Parkinson’s and other brain diseases as normal aging. Amarantus may or may not have the right treatment with their MANF, but by publicly discussing head injuries and their side effects, which include Parkinson’s disease, Alzheimer’s disease and other disorders in a symposium of their peers will be the make or break for new agreements or old share prices.
About AMBS Stock
Amarantus BioScience Inc., founded in January 2008, is a California-based development-stage biotechnology company focused on developing their intellectual property and proprietary technology to develop drug candidates to treat human diseases.
Last 5 Trading Sessions:
Date Last Change % Change Volume
01/04/13 0.1506 +0.0009 +0.60% 20,113,240
01/03/13 0.1497 -0.0223 -12.97% 39,804,402
01/02/13 0.1720 +0.0400 +30.30% 27,318,699
12/31/12 0.1320 +0.0240 +22.22% 12,705,200
12/28/12 0.1080 +0.0325 +43.05% 23,817,600
Bottom Line: Sure the commissions killed you, $20 in and out, and the capital gains tax due in 2014 will be a burden, but when you can turn $500 into that kind of money based on picking penny stocks at the right time, I don’t care who you are — you’re foolish to not want to learn how. With how AMBS stock traded on Friday and the upcoming scheduled appearances for Amarantus BioScience, you would be equally foolish to not have it on your penny stocks to watch list for next week.
If this is true...It appears they missed the conference...
will be presenting today at the 2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum,
I was able to sell 50,000 shares on etrade earlier this morning. Just wanted to recoup the last of my investment. Free shares from here for me.
Oh yes...The O/S they increased from 240,000,000 to 250,000,000 WOW!!!
Oh yes, there was a few million that was diluted, but nothing like the negatives are claiming!! And the 8Ks and 10ks explained the amount diluted and the fact that there are stipulations that must take place before they can be sold off by the recipients, am I correct??
Exactly my point! I seen someone claims the A/S is half a Bil...Last I knew it was about 250,000,000-ish. Can't seem to find any stock data website that list them at 500,000,000. Of course, once again he/she wasn't willing to provide supporting documentation or a link! How shocking is that!! LMAO
If you were to look into the PnDs, you would realize that a third party has paid for the newsletter PRs, not AMBS. Also, most of the newsletters only received about $2K. Not a large $$$ PnD campaign. Most likely an investor or a MM that has a large block of shares in the company.
Here is proof that AMBS is not ASCCE...I'm pretty sure the PR would have stated a new symbol when they stated the cusip number and name changed (by only dropping the "s" on BioScience(S))
http://www.otcmarkets.com/marketActivity/symbol-changes
http://www.otcmarkets.com/marketActivity/company-name-changes
http://www.otcmarkets.com/marketActivity/symbol-name-changes
Here is the MJFF Correction PR from 9 Nov 12 prior to today's 8K...
Original MJFF statement:
Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release - 11/07/2012 @ 7:30AM
Correction to MJFF Statement:
Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release - 11/09/2012 @ 5:42PM
Not gonna happen!
Great opportunity to pick up some more shares...not gonna be this cheap very much longer!
I agree with you FreightShaker! Steady gains almost always show better stability. Spikes almost always lead to free falls!
Nice half day close...Merry Christmas/Happy Holidays everyone!
News was realeased Thursday...
Based on it's content, many of us are speculating they are going to refrain from releasing anything until the OneMedForum.
http://ih.advfn.com/p.php?pid=nmona&article=55552252
News extract:
Dr. John W. Commissiong, CSO will present results of its Parkinson's disease neurorestoration animal studies at the OneMedForum SF 2013 conference on Tuesday, January 8, 2013 at 1:40pm PT.
Dr. Commissiong, Amarantus' Chief Scientific Officer, will be presenting results of the Parkinson's experiments including detailed review of behaviour, histology, densitometry and stereology data for MANF and how they compare with results obtained for GDNF. Thereafter, current Amarantus advisor Dr. Joseph Rubinfeld will provide his views on areas of significant commercial potential for MANF beyond Parkinson's disease.
NASDAQ uplisting info:
www.nasdaq.net/PublicPages/ListingStandards.aspx
https://listingcenter.nasdaqomx.com/Show_Doc.aspx?File=FAQsFees.html
NASDAQ Initial Listing Guide:
https://listingcenter.nasdaqomx.com/assets/initialguide.pdf
Very Well Stated!!!
He's broke...company's in debt. lol
Roy just purchased 10M @ .0003, so maybe he has some news getting ready to come out.
Statement of Changes in Beneficial Ownership - 12/20/2012 @ 11:39AM
Are you going to just keep changing your highest price of the day as it keeps going up as the day progresses??
LMAO
belleso Thursday, December 20, 2012 10:27:18 AM
Re: familyof5 post# 23988 Post # of 24047
0.06 is the roof today!
I like the news...reading between the lines...if it was not substantial news concerning the results of MANF, they would not be presenting the results at the conference in Jan! JMO